MYBF yields 4.79% · ABBV yields 3.06%● Live data
📍 MYBF pulled ahead of the other in Year 5
Combined, MYBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYBF + ABBV for your $10,000?
Muncy Bank Financial, Inc., together with its subsidiaries, provides banking products and services to individuals and businesses in Pennsylvania. It accepts savings, money market, and checking accounts, as well as demand, time, and certificates of deposit. The company's loan products include mortgage, home equity, vehicle, commercial mortgages, personal, commercial equipment loans, as well as business and real estate loans. It also offers investment services, such as wealth transition, retirement accounts, college savings strategies, insurance protection, portfolio analysis, brokerage services, tax-deferred investments, and tax-advantaged income; and wealth management and trust services comprising estate administration, investment management services, guardianship, and IRA/retirement accounts, as well as living/grantor, charitable, irrevocable, and special needs trusts. In addition, the company provides cash management services consisting of ACH origination, check positive pay, online wire transfer, and remote deposit capture services; merchant services; and telephone and electronic banking services, as well as debit and credit cards. It operates through eight offices located in Muncy, Hughesville, Clarkstown, Montoursville, Dewart, Avis, Linden, and Montgomery, Pennsylvania. The company was founded in 1893 and is based in Muncy, Pennsylvania.
Full MYBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.